A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 719-730

  Feldman, Gregory ^a   Maltais, François ^b   Khindri, Sanjeev ^c   Vahdati Bolouri, Mitra ^c   Church, Alison ^d   Fahy, William A ^c   Trivedi, Roopa ^d,e  

^a S Carolina Pharmaceutical Research   (United States)

^b LAVAL UNIVERSITY   (Canada)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

COPD; Long acting muscarinic antagonist; Non inferiority; Tiotropium; Umeclidinium

Indexed keywords

PLACEBO; SALBUTAMOL; TIOTROPIUM BROMIDE; UMECLIDINIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COPD ASSESSMENT TEST SCORE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX SCORE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

CHOLINERGIC ANTAGONISTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84963636152     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S102494     Document Type: Article

References (30)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [updated 2015]. Available from: http://www.goldcopd.org/. Accessed August 12, 2015.
2. World Health Organization – burden of COPD; 2015. Available from: http://www.who.int/respiratory/copd/burden/en/. Accessed August 19, 2015.
3. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(2):CD002876.
4. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
5. O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–840.
6. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81.
7. Eklira Genuair EMA assessment report; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002211/WC500132663.pdf. Accessed August 12, 2015.
8. Seebri Breezhaler EMA assessment report; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002430/WC500133771.pdf. Accessed September 23, 2015.
9. INCRUSE ELLIPTA: highlights of prescribing information; 2013. Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Incruse_Ellipta/pdf/INCRUSE-ELLIPTA-PI-PIL.PDF. Accessed August 12, 2015.
10. Summary of product characteristics: Incruse 55 micrograms inhalation powder; 2015. Available from: https://www.medicines.org.uk/emc/medicine/29394. Accessed August 12, 2015.
11. Chapman KR, Beeh KM, Beier J, et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting musca­rinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014;14:4.
12. Beier J, Kirsten AM, Mroz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10(4):511–522.
13. World Medical Association. World Medical Association Declara­tion of Helsinki: ethical principles for medical research involv­ing human subjects; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed September 29, 2015.
14. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
15. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umecli­dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486.
16. Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–1760.
17. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267–272.
18. Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79.
19. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.
20. Ingelheim B. Spiriva® 18 microgram, inhalation powder, hard capsule – package leaflet: information for the user; 2014. Available from: https://www.medicines.org.uk/emc/PIL.16286.latest.pdf. Accessed October 20, 2015.
21. GSK. Incruse® 55 micrograms inhalation powder, pre-dispensed – package leaflet: information for the user; 2015. Available from: https://www.medicines.org.uk/emc/PIL.29387.latest.pdf. Accessed October 20, 2015.
22. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124.
23. Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000;1(1):19–21.
24. Lewis JA, Machin D. Intention to treat – who should use ITT? Br J Cancer. 1993;68(4):647–650.
25. Church A, Beerahee M, Brooks J, Mehta R, Shah P. Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med. 2014;14:2.
26. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970–979.
27. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodila­tion with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1136–1142.
28. Summary of Product Characteristics: Spiriva 18 microgram inhalation powder, hard capsule. Available from: https://www.medicines.org.uk/emc/medicine/10039. Accessed January 27, 2016.
29. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological character­ization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260–270.
30. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–2048.